[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP18000844A - Anticuerpos de unión a tau - Google Patents

Anticuerpos de unión a tau

Info

Publication number
ECSP18000844A
ECSP18000844A ECIEPI2018844A ECPI201800844A ECSP18000844A EC SP18000844 A ECSP18000844 A EC SP18000844A EC IEPI2018844 A ECIEPI2018844 A EC IEPI2018844A EC PI201800844 A ECPI201800844 A EC PI201800844A EC SP18000844 A ECSP18000844 A EC SP18000844A
Authority
EC
Ecuador
Prior art keywords
tau
antibodies
union
binding
relates
Prior art date
Application number
ECIEPI2018844A
Other languages
English (en)
Inventor
Terence Seward Baker
Kerry Louise Tyson
Jean-Philippe Courade
Georges Mairet-Coello
David Edward Ormonde Knight
Patrick Downey
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of ECSP18000844A publication Critical patent/ECSP18000844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a anticuerpos de unión a Tau y fragmentos de unión de los mismos.
ECIEPI2018844A 2015-07-06 2018-01-05 Anticuerpos de unión a tau ECSP18000844A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15175519 2015-07-06

Publications (1)

Publication Number Publication Date
ECSP18000844A true ECSP18000844A (es) 2018-03-31

Family

ID=53524638

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI2018844A ECSP18000844A (es) 2015-07-06 2018-01-05 Anticuerpos de unión a tau

Country Status (23)

Country Link
US (4) US10344081B2 (es)
EP (1) EP3319984A1 (es)
JP (1) JP6937289B2 (es)
KR (1) KR102742965B1 (es)
CN (1) CN107849105B (es)
AR (1) AR105266A1 (es)
AU (1) AU2016289753C1 (es)
BR (1) BR112017028101A2 (es)
CA (1) CA2991264C (es)
CL (1) CL2018000042A1 (es)
CO (1) CO2017012974A2 (es)
EA (1) EA036821B1 (es)
EC (1) ECSP18000844A (es)
IL (1) IL256687B (es)
MA (2) MA42380A (es)
MX (1) MX2017015908A (es)
PE (1) PE20180499A1 (es)
PH (1) PH12017502180A1 (es)
TN (1) TN2017000543A1 (es)
TW (1) TWI748954B (es)
UY (1) UY36774A (es)
WO (1) WO2017005732A1 (es)
ZA (1) ZA201708128B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
IL300670B2 (en) 2015-06-05 2025-02-01 Genentech Inc Anti-tau antibodies and methods of use
KR102742965B1 (ko) 2015-07-06 2024-12-13 유씨비 바이오파마 에스알엘 타우 결합 항체
MA42377A (fr) 2015-07-06 2018-05-16 Ucb Biopharma Sprl Anticorps se liant à tau
JP7170316B2 (ja) 2016-05-02 2022-11-14 プロセナ バイオサイエンシーズ リミテッド タウ免疫療法
AU2017259038B2 (en) 2016-05-02 2024-05-23 Prothena Biosciences Limited Antibodies recognizing Tau
WO2018106776A2 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
CN110290801B (zh) 2016-12-07 2024-01-26 基因泰克公司 抗tau抗体和使用方法
US20200095327A1 (en) * 2017-02-08 2020-03-26 Dragonfly Therapeutics, Inc. Antibody heavy chain variable domains targeting the nkg2d receptor
IL268554B1 (en) 2017-02-08 2024-11-01 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
US11884732B2 (en) 2017-02-20 2024-01-30 Dragonfly Therapeutics, Inc. Proteins binding HER2, NKG2D and CD16
JOP20180014A1 (ar) 2017-02-27 2019-01-30 Teijin Pharma Ltd جسم مضاد متوافق مع البشر لعلاج أو الوقاية من الاضطرابات الإدراكية، وعملية لإنتاجه، وعامل لعلاج أو الوقاية من الاضطرابات الإدراكية باستخدامه
CU24636B1 (es) 2017-05-02 2022-12-12 Prothena Biosciences Ltd Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
TWI853617B (zh) 2017-10-16 2024-08-21 日商衛材R&D企管股份有限公司 抗tau抗體及其用途
KR20200118080A (ko) 2018-02-08 2020-10-14 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d 수용체를 표적화하는 항체 가변 도메인
KR20200132875A (ko) 2018-02-20 2020-11-25 드래곤플라이 쎄라퓨틱스, 인크. Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법
WO2020120644A1 (en) * 2018-12-13 2020-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) New anti tau svqivykpv epitope single domain antibody
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
WO2021205359A1 (en) * 2020-04-08 2021-10-14 Janssen Biotech, Inc. Anti-phf-tau antibodies and uses thereof
WO2021226193A1 (en) 2020-05-06 2021-11-11 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and clec12a
EP4171633A1 (en) 2020-06-25 2023-05-03 Merck Sharp & Dohme LLC High affinity antibodies targeting tau phosphorylated at serine 413
EP4271708A1 (en) * 2020-12-29 2023-11-08 Neurimmune AG Human anti-tau antibodies
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
ATE154642T1 (de) 1991-10-25 1997-07-15 Innogenetics Nv Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
US7408027B1 (en) 1991-12-06 2008-08-05 Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften Tools for the diagnosis and treatment of Alzheimer's disease
US6010913A (en) 1992-12-14 2000-01-04 N.V. Innogenetics S.A. Isolated human tau peptide
DK0737208T3 (da) 1993-12-21 2006-11-27 Innogenetics Nv Monoklonale antistoffer, der er specifikke for PHF-tau, hybridomaer, der secernerer dem, og antigen-genkendelse for disse antistoffer og deres anvendelsesmuligheder
ATE234324T1 (de) 1994-07-29 2003-03-15 Innogenetics Nv Monoklonale antikörper gegen ein epitop einer gewissen unterklasse oder form von phosphoryliertem tau, hybridome die diese sezernieren,antigenerkennung durch diese antikörper und deren verwendung
CA2527020A1 (en) 2003-07-01 2005-01-13 Celltech R & D Limited Modified antibody fab fragments
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
CN1721437A (zh) * 2004-07-13 2006-01-18 中南大学 一种与Tau蛋白相关的多肽抗原及抗体
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
KR101505201B1 (ko) 2005-12-12 2015-03-24 에이씨 이뮨 에스.에이. 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
AU2008353479B2 (en) * 2008-03-26 2014-02-20 Epitomics, Inc. Anti-VEGF antibody
CN101307108B (zh) * 2008-06-25 2012-04-04 南京川博生物技术有限公司 抗磷酸化Tau蛋白抗体及其在AD症异常磷酸化Tau蛋白水平测定上的用途
EP2334705B1 (en) 2008-09-26 2016-12-14 UCB Biopharma SPRL Biological products
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
CA3239368A1 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
NZ598356A (en) 2009-07-30 2014-06-27 Pfizer Vaccines Llc Antigenic tau peptides and uses thereof
EP2475682B1 (en) 2009-09-10 2018-01-31 UCB Biopharma SPRL Multivalent antibodies
SG189174A1 (en) 2010-10-11 2013-05-31 Biogen Idec Internat Neuroscience Gmbh Human anti-tau antibodies
EP2670434B1 (en) 2011-01-31 2018-12-26 Tau Bio-Logic Corp. Treatment of tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
CA2848346A1 (en) 2011-09-19 2013-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
KR102048382B1 (ko) 2011-11-11 2019-11-25 유씨비 바이오파마 에스피알엘 알부민 결합 항체 및 이의 결합 단편
PT2794654T (pt) 2011-12-20 2019-09-10 Janssen Biotech Inc Anticorpos anti-phf-tau e suas utilizações
JP6293731B2 (ja) 2012-04-05 2018-03-14 エーシー イミューン エス．エー． ヒト化タウ抗体
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
WO2014016737A1 (en) 2012-07-24 2014-01-30 Pfizer Inc. Novel chicken monoclonal antibodies against human phosphorylated tau and uses thereof
AU2013302540B2 (en) * 2012-08-16 2018-02-15 Ipierian, Inc. Methods of treating a tauopathy
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
BR112015023262B8 (pt) 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
LT3083680T (lt) 2013-12-20 2020-04-10 F. Hoffmann-La Roche Ag Humanizuoti anti-tau(ps422) antikūnai ir jų naudojimo būdai
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
IL300670B2 (en) 2015-06-05 2025-02-01 Genentech Inc Anti-tau antibodies and methods of use
MA42377A (fr) 2015-07-06 2018-05-16 Ucb Biopharma Sprl Anticorps se liant à tau
KR102742965B1 (ko) 2015-07-06 2024-12-13 유씨비 바이오파마 에스알엘 타우 결합 항체
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها

Also Published As

Publication number Publication date
EA036821B1 (ru) 2020-12-23
MA42380A (fr) 2018-05-16
BR112017028101A2 (pt) 2018-09-04
US11746145B2 (en) 2023-09-05
CO2017012974A2 (es) 2018-03-09
KR102742965B1 (ko) 2024-12-13
IL256687B (en) 2022-02-01
EA201890169A1 (ru) 2018-10-31
WO2017005732A1 (en) 2017-01-12
TWI748954B (zh) 2021-12-11
US20230331833A1 (en) 2023-10-19
CL2018000042A1 (es) 2018-06-01
US20190375829A1 (en) 2019-12-12
MX2017015908A (es) 2018-03-15
JP2018519833A (ja) 2018-07-26
PE20180499A1 (es) 2018-03-09
AU2016289753B2 (en) 2020-11-26
US20180194832A1 (en) 2018-07-12
MA41669A1 (fr) 2018-05-31
US10344081B2 (en) 2019-07-09
PH12017502180A1 (en) 2018-05-28
UY36774A (es) 2017-01-31
CN107849105A (zh) 2018-03-27
US10906966B2 (en) 2021-02-02
TN2017000543A1 (en) 2019-04-12
TW201713688A (zh) 2017-04-16
CA2991264A1 (en) 2017-01-12
ZA201708128B (en) 2019-05-29
AU2016289753C1 (en) 2021-08-05
AU2016289753A1 (en) 2017-12-14
CN107849105B (zh) 2021-09-17
CA2991264C (en) 2023-10-10
NZ737843A (en) 2024-05-31
KR20180027566A (ko) 2018-03-14
EP3319984A1 (en) 2018-05-16
AR105266A1 (es) 2017-09-20
IL256687A (en) 2018-03-29
JP6937289B2 (ja) 2021-09-22
US20210139574A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
ECSP18000844A (es) Anticuerpos de unión a tau
ECSP18000887A (es) Anticuerpos de unión a tau
IL265321B1 (en) Cd3 binding antibodies
DK3625259T3 (da) Anti-sirpalpha-antistoffer
CL2017002752A1 (es) Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales
EP3569709A4 (en) ANTI-GPC3 ANTIBODIES
EP3661558A4 (en) ANTI-IL1RAP ANTIBODIES
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
EA202092435A2 (ru) Моноклональные антитела против bcma
HUE042039T2 (hu) Humán CD3 kötõ antitest
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
BR112018010360A2 (pt) fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
CR20160388A (es) Terapias de combinación con anticuerpos anti-cd38
IL273393A (en) New epsilon anti-CD3 antibodies
DK3242892T3 (da) Modificerede april-bindende antistoffer
EP3691447A4 (en) ANTI-TRANSTHYRETINE ANTIBODY
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3596126A4 (en) NEW ANTI-TRKB ANTIBODIES
DK3253785T3 (da) Hidtil ukendte egfr-bindingsproteiner
EP3532034A4 (en) ANTI-APOE ANTIBODY
DK3484921T3 (da) Anti-IL-22R antistoffer
EP3604518A4 (en) ANTI-GPR20 ANTIBODY
EP3720492A4 (en) ANTI-RSPO3 ANTIBODIES
IT201700083637A1 (it) Nuovi anticorpi